Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 3NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 11Leukemia, Myelomonocytic, Acute 10Leukemia, Monocytic, Acute 10Leukemia, Megakaryoblastic, Acute 10Leukemia, Erythroblastic, Acute 10Congenital Abnormalities 8Breast Neoplasms 8Anemia, Refractory, with Excess of Blasts 5Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Eosinophilic, Acute 4Leukemia, Basophilic, Acute 4Leukemia 4Gliosarcoma 4Glioblastoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Melanoma 3Medulloblastoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Blast Crisis 3Wilms Tumor 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thrombocythemia, Essential 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2

Interventions

Peripheral Blood Stem Cell Transplantation 5fludarabine phosphate 4Radiotherapy 4Antilymphocyte Serum 4Vincristine 3Vinblastine 3Procarbazine 3Prednisolone 3Methylprednisolone 3Melphalan 3Filgrastim 3Doxorubicin 3Cyclophosphamide 3Chlorambucil 3Busulfan 3Bortezomib 3Bevacizumab 3tipifarnib 2Vorinostat 2Sorafenib 2Oxaliplatin 2Mycophenolic Acid 2Methotrexate 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Dacarbazine 2Cyclosporine 2Bleomycin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Recurrence × tipifarnib × Clear all
NCT02210858 2018-06-04

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1/2 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00383474 2015-04-15

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

National Cancer Institute (NCI)

Phase 1 Completed
35 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡